Sanofi and Advent International (Advent) have finished negotiations for the acquisition of Zentiva – Sanofi’s European generics business. Advent and the companies have signed a Share Purchase Agreement worth €1.9 billion (enterprise value). The companies announced that they had entered into exclusive talks on April 17, 2018.
The signing of this Share Purchase Agreement marks a critical step on the way to the closing of the deal and the transfer of the Zentiva business to Advent, that is anticipated during the course of the fourth quarter of 2018.
The transaction remains subject to the approval of the competent regulatory authorities.